Loqtorzi

(toripalimab)

Uses, side effects, dosage information & price range

Topalliance Biosciences Europe Limited

About this medicine

Loqtorzi, in combination with cisplatin and gemcitabine, is indicated for the first-line treatment of adult patients with recurrent, not amenable to surgery or radiotherapy, or metastatic nasopharyngeal carcinoma. Loqtorzi, in combination with cisplatin and paclitaxel, is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma.

Common Substitutes & Alternatives

These medicines share the same salt composition or therapeutic category and can be used as substitutes under professional medical supervision.

PoherdyComposition: pertuzumabOrganon N.V.

Price on RequestView Details →

MekinistComposition: trametinibNovartis Europharm Limited

Price on RequestView Details →

VijoiceComposition: alpelisibNovartis Europharm Limited

Price on RequestView Details →

KisqaliComposition: ribociclibNovartis Europharm Limited

Price on RequestView Details →

TecartusComposition: brexucabtagene autoleucelKite Pharma EU B.V.

Price on RequestView Details →

Key Information

Salt / Composition

toripalimab